TBIO (Codex DNA) Total Business Assets

This price chart illustrating the trading dynamics of Telesis Bio, Inc. (TBIO) total assets, valued at 89.40, confirms the business's macro-resilience driven by the indispensability of its DNA synthesis technologies. The model relies on long-term customer loyalty from those purchasing consumables for the equipment. However, high production costs associated with low-volume system deliveries constrain the company's ability to reduce unit costs.

Telesis Bio, Inc. (TBIO) dominance in the automated DNA/RNA synthesis segment via BioXp systems defines its resource structure, where balance sheet assets, reconstructed through return on assets (ROA), reflect the company's aggregate value of assets and liabilities. This metric measures capital efficiency amid borrowing cost volatility, allowing investors to assess the business's actual material base based on market equilibrium dynamics.